Here are the 424B prospectus supplements from Editas Medicine, Inc. (EDIT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow EDIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDIT filings page.
Editas Medicine is offering 55,555,556 shares of common stock and accompanying warrants at a combined public offering price of $2.25 per share-plus-warrant. The offering includes detachable common stock warrants exercisable at $3.50 (or pre-funded alternatives) and is expected to raise approximately $117.0 million in net proceeds to fund development of EDIT-401, clinical and manufacturing costs, and general corporate purposes. The offering assumes 153,461,838 shares outstanding after the offering (assuming no exercise of the new warrants).
Editas Medicine is offering shares of common stock, pre-funded warrants and accompanying common stock warrants. The prospectus supplement describes the securities' structure, including combined purchase units (each unit pairs a share or pre-funded warrant with a warrant), exercise prices, ownership limitation mechanics (4.99% or 9.99% initially, increaseable to 19.99% after notice), and the limited exercisability windows for the common stock warrants tied to Phase 1 EDIT-401 clinical data or three years from issuance. The filing discloses 97,906,282 shares outstanding as of April 30, 2026, cash and cash equivalents of $123.6 million as of March 31, 2026, Nasdaq listing under the symbol EDIT, and that net tangible book value was $4.4 million ( $0.05 per share) as of March 31, 2026. Use of proceeds is stated as funding EDIT-401 clinical development and manufacturing, plus working capital and general corporate purposes.